Everest Management Corp’s AbbVie ABBV Stock Holding History

Everest Management Corp’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$315K	Sell	1,252 -112	-8%	-$24.1K	0.12%	68
2026 Q1	$297K	Buy	1,364 +303	+29%	+$67.2K	0.15%	55
2025 Q4	$242K	Sell	1,061 -76	-7%	-$17.3K	0.14%	57
2025 Q3	$263K	Buy	1,137 +21	+2%	+$4.28K	0.17%	56
2025 Q2	$207K	Buy	1,116 +72	+7%	+$13.4K	0.15%	65
2025 Q1	$219K	Buy	+1,044	New	+$203K	0.2%	48

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Everest Management Corp's ABBV Position: Q2 2026 in Review

Everest Management Corp reduced its AbbVie (ABBV) stake by 8.2% in Q2 2026, selling an estimated $24.1K and leaving 1,252 shares worth $315K. The position accounts for 0.12% of the portfolio, ranked #68.

Everest Management Corp first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Everest Management Corp held 1,252 shares of AbbVie worth $315K as of Q2 2026.
Everest Management Corp sold 112 AbbVie shares in Q2 2026, an estimated $24.1K.
AbbVie made up 0.12% of Everest Management Corp's portfolio in Q2 2026, its #68 holding.
Everest Management Corp first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Everest Management Corp's 13F filing for Q2 2026, filed 7 Aug 2026.